Revenue declined 9% year-over-year to PLN 327.8m, but EBITDA rose 4% to PLN 80.9m, driven by higher recurring revenues and improved margins. The group expanded its robotics and IT segments, spun off its cardiac marker R&D, and paid a record dividend.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.